The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
Open accessAbstract
BACKGROUND: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications. METHODS: We compared the efficacy and safety of peginterferon alfa-2a (180 microg once weekly) plus placebo, peginterferon alfa-2a plus lamivudine (100 mg daily), and lamivudine alone in 177, 179, and 181 patients with HBeAg-negative chronic hepatitis B, respectively. Patients were treated for 48 weeks and followed for an additional 24 weeks. RESULTS: After 24 weeks of follow-up, the percentage of patients with normalization of alanine aminotransferase levels or hepatitis B virus (HBV) DNA levels below 20,000 copies per milliliter was significantly higher with peginterferon alfa-2a monotherapy (59 percent and 43 percent, respectively) and peginterferon alfa-2a plus lamivudine (60 percent and 44 percent) than with lamivudine monotherapy (44 percent, P=0.004 and P=0.003, respectively; and 29 percent, P=0.007 and P=0.003, respectively). Rates of sustained suppression of HBV DNA to below 400 copies per milliliter were 19 percent with peginterferon alfa-2a monotherapy, 20 percent with combination therapy, and 7 percent with lamivudine alone (P<0.001 for both comparisons with lamivudine alone). Loss of hepatitis B surface antigen occurred in 12 patients in the peginterferon groups, as compared with 0 patients in the group given lamivudine alone. Adverse events, including pyrexia, fatigue, myalgia, and headache, were less frequent with lamivudine monotherapy than with peginterferon alfa-2a monotherapy or combination therapy. CONCLUSIONS: Patients with HBeAg-negative chronic hepatitis B had significantly higher rates of response, sustained for 24 weeks after the cessation of therapy, with peginterferon alfa-2a than with lamivudine. The addition of lamivudine to peginterferon alfa-2a did not improve post-therapy response rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Self-citationHistological grading and staging of chronic hepatitis
Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., Denk, H., Desmet, V., Korb, G., MacSween, R. N. M., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,029
Lai, C. L., Ratziu, V., Yuen, M.-F., & Poynard, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15108-2 · Cited by 1,727
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432301 · Cited by 1,220
Self-citationAdefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T.-T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Wulfsohn, M. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021812 · Cited by 995
Self-citationBailon, P., Palleroni, A., Schaffer, C. A., Spence, C. L., Fung, W.-J., Porter, J. E., Ehrlich, G. K., Pan, W., Xu, Z.-X., Modi, M. W., et al. (2001) · Bioconjugate Chemistry · doi:10.1021/bc000082g · Cited by 611
Hepatitis B e antigen-negative chronic hepatitis B
Hadziyannis, S. J., & Vassilopoulos, D. (2001) · Hepatology · doi:10.1053/jhep.2001.27834 · Cited by 554
Self-citationEASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B
Jury, T. E. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00378-7 · Cited by 512
Chronic hepatitis B: Update of recommendations† ‡
Lok, A. S. F., & McMahon, B. J. (2004) · Hepatology · doi:10.1002/hep.20110 · Cited by 500
Cooksley, W. G. E., Piratvisuth, T., Lee, S. ‐., Mahachai, V., Chao, Y. ‐., Tanwandee, T., Chutaputti, A., Chang, W. Y., Zahm, F. E., & Pluck, N. (2003) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00450.x · Cited by 475
Self-citationFunk, M. L., Rosenberg, D. M., & Lok, A. S. F. (2002) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2002.00304.x · Cited by 354
Brunetto, M. R., Oliveri, F., Coco, B., Leandro, G., Colombatto, P., Gorin, J. M., & Bonino, F. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00266-5 · Cited by 331
Self-citationPapatheodoridis, G. V., Manesis, E., & Hadziyannis, S. J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00094-5 · Cited by 246
Self-citationSantantonio, T., Mazzola, M., Iacovazzi, T., Miglietta, A., Guastadisegni, A., & Pastore, G. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80076-8 · Cited by 242
&NA; (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200104000-00030 · Cited by 232
Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B
Manesis, E. K., & Hadziyannis, S. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.25524 · Cited by 216
Self-citationLampertico, P., Del Ninno, E., Viganò, M., Romeo, R., Donato, M. F., Sablon, E., Morabito, A., & Colombo, M. (2003) · Hepatology · doi:10.1053/jhep.2003.50148 · Cited by 215
Lok, A. S.-F., Zoulim, F., LOCARNINI, S. A., Mangia, A., Niro, G. A., Decraemer, H., Maertens, G. G., Hulstaert, F., de Vreese, K., & Sablon, E. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.10.3729-3734.2002 · Cited by 152
Cerebral dysfunction in chronic hepatitis C infection
Forton, D. M., Taylor-Robinson, S. D., & Thomas, H. C. (2003) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00416.x · Cited by 119
Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update*
Liaw, Y., Leung, N. W. Y., Guan, R., Lau, G. K. K., & Merican, I. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.03037.x · Cited by 100
Self-citationThe impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B
Richman, D. D. (2000) · Hepatology · doi:10.1053/jhep.2000.18194 · Cited by 85
Assessment of Depression in Patients with Chronic Viral Hepatitis: Effect of Interferon Treatment
Koskinas, J. S., Merkouraki, P., Manesis, E. K., & Hadziyannis, S. (2002) · Digestive Diseases · doi:10.1159/000067682 · Cited by 55
Self-citation
Cited by
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Self-citationAASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2016) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,006
Metadata
- Authors
- Marcellin, P., Lau, G. K. K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., Lu, Z.-M., Piratvisuth, T., Germanidis, G., Yurdaydin, C., Diago, M., Gurel, S., Lai, M.-Y., Button, P., & Pluck, N.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-09-16
- Volume
- 351
- Issue
- 12
- Pages
- 1206-1217
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2169631718
- Cited by
- 1,145
- References
- 22
- FWCI
- 60.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.